Experimental study of enhanced anti-pancreatic cancer effects by combination treatment with HUVEC vaccine and gemcitabine / 中国药理学通报

ABSTRACT

Aim To investigate whether low dose gem- citabine ( GEM) could enhance the anti-pancreatic cancer effects of human umbilical vein endothelial cell (HUVEC) vaccine.Methods C57BL/6 mice were randomly divided into four groups; PBS control group, GEM group, HUVEC vaccine group and HUVEC vaccine combined GEM group ( HUVEC-GEM group).Mice were inoculated with Pan02 pancreatic cancer cells to establish a subcutaneous xenograft model to observe tumor growth and adverse reactions in tumor bearing mice.Whether GEM could enhance the immune responses induced by HUVEC vaccine was determined by ELISA analysis of the immune serum, splenic lymphocyte proliferation assay, cytotoxic T lymphocyte killing assay and IFN-7 content assay.Results The results of subcutaneous transplantation tumor model showed that the introduction of GEM into the HU-VEC vaccine treatment could enhance the therapeutic anti-pancreatic cancer effects of HUVEC vaccine.Enzyme-linked immunoassay results confirmed that GEM acted as an immune adjuvant could effectively increase the HUVEC antibodies and I FN-7 level in the immune serum of mice.The results of lymphocyte proliferation experiment and CTL killing activity assay indicated that GEM could effectively enhance the spleen lymphocyte transformation activity and CTL killing ability of HUVEC vaccine immunized mice.Conclusions Low dose GEM could enhance the immune responses induced by HUVEC vaccine and thus enhance the anti- Pan02 pancreatic cancer effects of HUVEC vaccine.